Literature DB >> 26715302

N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.

Dezhi Li1,2, Jie Liu2, Li Zhang2, Tianshu Xu2,3, Junheng Chen2,3, Liping Wang4, Qi Zhao5,6.   

Abstract

The Human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER) is targeted by broadly neutralizing antibodies (e.g. 2F5, 4E10, Z13e and m66.6), which makes this region a promising target for vaccine design. One strategy to elicit neutralizing antibodies against the MPER epitope is to design peptide immunogens mimicking neutralization structures. To probe 2F5-like neutralizing antibodies, two yeast-displayed antibody libraries from peripheral blood mononuclear cells from a HIV-1 patient were screened against the 2F5 epitope peptide SP62. Two 2F5-like antibodies were identified that specifically recognized SP62. However, these antibodies only weakly neutralized HIV-1 primary isolates. The epitopes recognized by these two 2F5-like antibodies include not only the 2F5 epitope (amino acids (aa) 662-667 in the MPER) but also several other residues (aa 652-655) locating at the N-terminus in SP62. Experimental results suggest that residues of SP62 adjacent to the 2F5 epitope influence the response of broadly neutralizing 2F5-like antibodies in vaccination. Our findings may aid the design of vaccine immunogens and development of therapeutics against HIV-1 infection.

Entities:  

Keywords:  2F5; HIV-1; membrane proximal external region (MPER); neutralizing antibody; yeast display

Mesh:

Substances:

Year:  2015        PMID: 26715302      PMCID: PMC8200909          DOI: 10.1007/s12250-015-3664-6

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  31 in total

1.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

Authors:  Qi Zhao; Mahiuddin Ahmed; Hong-fen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  J Biol Chem       Date:  2015-04-07       Impact factor: 5.157

2.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling.

Authors:  Benjamin J Hackel; Atul Kapila; K Dane Wittrup
Journal:  J Mol Biol       Date:  2008-06-24       Impact factor: 5.469

4.  One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector.

Authors:  Qi Zhao; Yin-Wah Chan; Susanna Sau-Tuen Lee; Wing-Tai Cheung
Journal:  Protein Expr Purif       Date:  2009-08-13       Impact factor: 1.650

5.  Yeast display of engineered antibody domains.

Authors:  Qi Zhao; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Rational modifications of HIV-1 envelope glycoproteins for immunogen design.

Authors:  S Phogat; R Wyatt
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

7.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 8.  Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

Authors:  George Lin; Peter L Nara
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

9.  In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Authors:  Xiaoying Shen; Robert J Parks; David C Montefiori; Jennifer L Kirchherr; Brandon F Keele; Julie M Decker; William A Blattner; Feng Gao; Kent J Weinhold; Charles B Hicks; Michael L Greenberg; Beatrice H Hahn; George M Shaw; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  bNAber: database of broadly neutralizing HIV antibodies.

Authors:  Alexey M Eroshkin; Andrew LeBlanc; Dana Weekes; Kai Post; Zhanwen Li; Akhil Rajput; Sal T Butera; Dennis R Burton; Adam Godzik
Journal:  Nucleic Acids Res       Date:  2013-11-07       Impact factor: 16.971

View more
  3 in total

1.  Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.

Authors:  Dezhi Li; Rui Gong; Jun Zheng; Xihai Chen; Dimiter S Dimitrov; Qi Zhao
Journal:  Biochem Biophys Res Commun       Date:  2017-02-13       Impact factor: 3.575

2.  Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Authors:  Carolina Beltran-Pavez; Carolina B Ferreira; Alberto Merino-Mansilla; Amanda Fabra-Garcia; Maria Casadella; Marc Noguera-Julian; Roger Paredes; Alex Olvera; Isabel Haro; Christian Brander; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

Review 3.  Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.

Authors:  Guangyu Zhou; Qi Zhao
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.